Replies to post #158256 on Biotech Values

[iwfal]

GERN -

The purpose of the study in ET was to provide proof of concept for the potential use of imetelstat as a treatment for various other hematologic myeloid malignancies, including myelofibrosis, myelodysplastic syndromes and acute myeloid leukemia. However, the ET data exceeded our expectations, and we are currently working with expert advisers to assess whether there is any potential for the further development of imetelstat in ET.

Well, I'd agree that the imetelstat results do appear to be substantially better than either HU or jakafi. And did they not even provide a clue as to when they would start a ph iii? How long can that take?

A total of 20 patients have been enrolled in the trial, which includes 18 patients with ET and 2 patients with polycythemia vera.

I find it fascinating that they would stop enrollment at 2 PV patients. Either:

a) The results were spectacularly bad - which wouldn't bode well for MF.

OR

b) They are just completely focused on being an employment shop. Literally wiling away the hours.

It really is odd.


BTW - regarding the cancellation of the Multiple Myeloma trial, I've noted before that their behavior with regard to Myeloma is odd. And in my experience 'odd' biotech behavior normally means something bad.